Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06293300 · ClinicalTrials.gov registry record · Phase 2
Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)
A Phase 2 study of Traumatic Brain Injury, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06293300: Recruiting Phase 2 study of Traumatic Brain Injury, sponsored by University of Miami.
NCT06293300 is a Phase 2 study of Traumatic Brain Injury that is actively recruiting participants, run by University of Miami. The registered enrollment target is 50 participants, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06293300, a Phase 2 study of Traumatic Brain Injury, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to understand and treat Traumatic Brain Injury (TBI) associated photophobia (light sensitivity) and its impact on visual function.
Primary Outcome
The change in numerical rating of average photophobia during the past week, ranging from 0 (for "no ocular pain") to 10 ("the most intense ocular pain imaginable").
Conditions Studied
Interventions
- DRUG BoNT A
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
What NCT06293300 shows while recruiting
NCT06293300 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Traumatic Brain Injury appearing as the primary indexed condition, and to 1 intervention - of which BoNT A is the first listed.
NCT06293300 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06293300 about?
NCT06293300 is a clinical study titled "Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)". The purpose of this research is to understand and treat Traumatic Brain Injury (TBI) associated photophobia (light sensitivity) and its impact on visual function.
What is the current status of trial NCT06293300?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2024-09-30. Estimated completion is 2026-09-30.
What conditions does trial NCT06293300 study?
This clinical trial studies the following conditions: Traumatic Brain Injury.
What interventions are being tested in trial NCT06293300?
The interventions under investigation include: BoNT A (DRUG).
Who is sponsoring clinical trial NCT06293300?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06293300 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Traumatic Brain Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06293300's enrollment target sits among peer trials
50 116th of 171 higher than 51 of 171 other Traumatic Brain Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Traumatic Brain Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Neurotrauma by Depolarization Inhibition With Combination Therapy (INDICT)
RECRUITING · Phase 2
-
Hyperbaric Oxygen Brain Injury Treatment Trial
RECRUITING · Phase 2
-
High Intensity Step Training After Traumatic Brain Injury
RECRUITING · Phase 2
-
Sildenafil for Microvasculopathy in Chronic TBI
RECRUITING · Phase 2
-
Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI
RECRUITING · Phase 2
-
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI